Koen Augustyns full professor - dean

Koen Augustyns

Lectures at Scientific Symposia

  1. “Synthesis and properties of sugar modified oligonucleotides” Derde Forum der Farmaceutische Wetenschappen, Houffalize, Belgium (15-16/03/1991)
  2. “Dipeptidylpeptidase IV, a new target in the development of antidiabetic agents” Netherlands Federation for Innovative Drug Research : Geneesmiddelendagen, Lunteren, The Netherlands (02-03/10/2000)
  3. “Design, synthesis and biological activity of glutathionylspermidine synthetase inhibitors” EU-COST Action B9 on Chemotherapy of Protozoal Infections, Hamburg, Germany (29-31/08/2002)
  4. “Dipeptidylpeptidase IV inhibitors : new drugs for the treatment of type 2 diabetes.” UCL, Louvain-la-Neuve, Belgium (29/04/2003)
  5. “Dipeptidylpeptidase IV inhibitors : new drugs for the treatment of type 2 diabetes.” University of Kuopio, Kuopio, Finland (05/09/2003)
  6. “Dipeptidylpeptidase IV inhibitors : new drugs for the treatment of type 2 diabetes.” Workshop Bilateral Cooperation Flanders-Poland, University of Antwerp, Belgium (24/09/2003)
  7. “Dipeptidylpeptidase IV inhibitors : new drugs for the treatment of type 2 diabetes.” Symposium organized by the division of pharmacochemistry of the Royal Chemical Society of the Netherlands, Free University of Amsterdam, The Netherlands (05/03/2004)
  8. “Targeting trypanosomatids” XIXth International Symposium on Medicinal Chemistry, Istanbul, Turkey (29/08-02/09/2006)
  9. “Diaryl phosphonates as irreversible inhibitors of serine proteases” 21èmes Journées franco-belges de Pharmacochimie, Namur, Belgium (10-11/05/2007)
  10. “Medicinal chemistry aspects of DPP inhibitors” 3rd International conference on dipeptidyl peptidases and related proteins, Antwerp, Belgium (23-25/04/2008)
  11. “Discovery of dipeptidyl-peptidase (DPP) inhibitors: DPP IV inhibitors as a novel class of anti-diabetic drugs” FIGON, Dutch Medicines Days, Lunteren, The Netherlands (06-08/10/2008)
  12. “Diaryl Phosphonates, Irreversible Serine Protease Inhibitors with Potential in Drug Discovery” Knowledge for Growth, Gent, Belgium (07/05/2009)
  13. “Irreversible Serine Protease Inhibitors: Useful Tools in Drug Discovery” 45ièmes Rencontres Internationales de Chimie Thérapeutique: Drug Discovery and Selection, Orléans, France (01-03/07/2009)
  14. “Diarylphosphonates: irreversible serine protease inhibitors useful in drug discovery” X Jornadas de Quimica Farmaceutiva, Vitoria, Spain (28-29/10/2010)
  15. “Inhibitors of dipeptidyl peptidases: From drug discovery to the clinic” 2nd National Meeting on Medicinal Chemistry, Coimbra, Portugal (28-30/11/2010)
  16. “Irreversible inhibitors of serine proteases: Tools or drugs?” 241st Meeting of the American Chemical Society (ACS), Anaheim, USA (27-31/03/2011)
  17. “Covalent Binders in Drug Discovery” FinMedChem 2011, Helsinki, Finland (15-16/09/2011)
  18. “Innovation and the Pharmaceutical Industry: A marriage going downhill?” ActUA, Antwerp, Belgium (01/12/2011)
  19. “Irreversible Inhibitors of Serine Proteases: Tools or Drugs?” Belgian Medchem Symposium 2012, Liège, Belgium (30/11/2012)
  20. “The use of irreversible serine protease inhibitors in drug discovery and chemical biology” Protease symposium, Munich, Germany (14/12/2012)
  21. “Probes to image the catalytic activity of serine proteases” Novartis, Basel, Switzerland (25/09/2013)
  22. “Probes to image the catalytic activity of serine proteases” Janssen R&D, Beerse, Belgium (12/12/2013)
  23. “Probes to image the catalytic activity of serine proteases” 9th Status Seminar Chemical Biology, Frankfurt, Germany (21-22/01/2014)
  24. “Novel non-nucleoside reverse transcriptase inhibitors for the prevention of HIV/AIDS” 5th European Workshop in Drug Synthesis, Siena, Italy (18-23/05/2014)
  25. “Medicinal Chemistry of novel anti-infectives” InnovaBalt Seminar, Riga, Latvia (27-28/05/2014)
  26. “Activity-based probes to image the catalytic activity of serine proteases” Flemish Training Network Life Sciences, Applying Chemical Tools to Study Biology, Antwerp, Belgium (11-12/06/2014)
  27. “Activity-based probes to image proteolytic activity in oncology” 1st International Congress: from drug discovery to drug delivery, Athens, Greece (13-15/11/2014)
  28. “Activity-based probes to image proteolytic activity in oncology” Drug Discovery Conference, Riga, Latvia (27-29/08/2015)
  29. “Development of a novel microbicide for the prevention of HIV/AIDS” 10th AFMC International Medicinal Chemistry Symposium (AIMECS2015), Jeju, South-Korea (18-21/10/2015)
  30. “Activity-based probes to image proteolytic activity in oncology” Louvain Drug Research Institute, UCL, Louvain-la-Neuve, Belgium (08/02/2016)
  31. “Activity-based probes and bioorthogonal chemistry: novel tools for chemical biology and drug discovery” BrazMedChem 2016, Armação Dos Búzios, Rio de Janeiro, Brazil (27-30/11/2016)
  32. “Activity-based probes and bioorthogonal chemistry: novel tools for chemical biology and drug discovery” LACDR Spring Symposium 2017, Leiden, The Netherlands (04/05/2017)
  33. “Irreversible protease inhibitors, activity-based probes and bioorthogonal chemistry: novel tools for chemical biology” MedChemTrain Summer School, Coimbra, Portugal (16/06/2017)
  34. “Development of a novel microbicide for the prevention of HIV/AIDS” MedChemTrain Summer School, Coimbra, Portugal (16/06/2017)
  35. “Activity-based probes and bioorthogonal chemistry: novel tools for chemical biology” 11th AFMC International Medicinal Chemistry Symposium (AIMECS2017), Melbourne Australia (23-26/07/2017)
  36. “De nieuwe geneesmiddelen van 2017” Farmant, Antwerp, Belgium (19/12/2017)
  37. “De nieuwe geneesmiddelen van 2018” Farmant, Antwerp, Belgium (17/12/2018)
  38. “University of Antwerp and the Faculty FBD” Saint Louis University, Baguio, The Philippines (28/11/2019)
  39. “Regulated Necrotic Cell Death: Novel Opportunities for Medicinal Chemistry”,  The 18th Asian Chemical Congress (ACC) and the 20th General Assembly of the Federation of Asian Chemical Societies, Taipei, Taiwan (08-12/12/2019)
  40. “De nieuwe geneesmiddelen van 2019” Farmant, Antwerp, Belgium (04/02/2020)
  41. “Regulated Necrotic Cell Death: Novel Opportunities for Drug Discovery”, FIGON & EUFEPS European Medicines Days, Leiden, The Netherlands (02/06/2022)
  42. “Regulated Necrotic Cell Death: Novel Opportunities for Drug Discovery”, The DrugTech RC of the University of Eastern Finland Seminar Series, online (19/10/2022)